Excessive dosing and polypharmacy of antipsychotics caused by pro re nata in agitated patients with schizophrenia
Psychiatry and Clinical Neurosciences 2013;
67: 345–351
Excessive dosing and polypharmacy of antipsychotics causedby pro re nata in agitated patients with schizophrenia
Junichi Fujita, MD,1,3* Atsushi Nishida, PhD,1,2 Mutsumi Sakata, BS,4 Toshie Noda, MD1 andHiroto Ito, PhD11
Department of Social Psychiatry,
National Institute of Mental Health, National Center of Neurology and Psychiatry,2
Tokyo Institute of Psychiatry,
Tokyo, 3
Department of Child and Adolescent Psychiatry,
Kanagawa Children's MedicalCenter,
Kanagawa and 4
Sasaguri Hospital,
Fukuoka, Japan
Aims: It has been recommended that for patients
Results: Of 413 patients, 312 (75.5%) were pre-
with schizophrenia, antipsychotics should be pre-
scribed p.r.n. for agitated status. Of those, 281
scribed simply, using an optimal dose. However, pro
(90.1%) were prescribed p.r.n. antipsychotics. The
re nata (p.r.n., meaning to use on an as-needed basis)
total doses were significantly higher and more com-
antipsychotics may increase the risk of excessive
pounded in case patients prescribed p.r.n. antipsy-
dosing (defined as mean chlorpromazine-equivalent
chotics than in those who were not. Seventeen
doses above 1000 mg) and polypharmacy (combina-
patients (4.1%) were actually administered p.r.n.
tion use of different antipsychotics). This study
antipsychotics. Their total medication, including
aimed to investigate the increased risk caused by
p.r.n. on the current day, represented excessive
dosing or polypharmacy of antipsychotics.
Method: The subjects included 413 patients with
Conclusion: The use of p.r.n. antipsychotics may
schizophrenia from 17 acute psychiatric wards in
cause hidden excessive dosing and polypharmacy.
nine hospitals. Over a 24-h period on a survey day,
Our results indicate the importance of careful moni-
data on regular medication and the use of p.r.n. were
toring of p.r.n. antipsychotics to agitated patients
collected. The analysis focused on p.r.n. antipsychot-
with schizophrenia.
ics in agitated patients. We used McNemar's test toevaluate differences in the proportions of patients
Key words: acute mental health care, antipsychotics,
prescribed antipsychotics with excessive dosing or
polypharmacy, pro re nata, schizophrenia.
polypharmacy before (i.e., regular medication only)and after prescribed p.r.n. antipsychotics were addedto regular medication (i.e., regular medication plusp.r.n. antipsychotics).
THERE IS NO evidence that a combination of shows that excessive dosing of antipsychotics
antipsychotics is more effective than a single
increases side-effects1,3 and mortality.4 Guidelines
antipsychotic.1 In addition, combining antipsychot-
and algorithms have recommended that antipsy-
ics is a major cause of excessive dosing,2 and evidence
chotic medications for patients with schizophreniabe prescribed simply, using an optimal dose.5,6However, there are discrepancies between these
*Correspondence: Junichi Fujita, MD, Department of Child and
guidelines or algorithms and actual prescription pat-
Adolescent Psychiatry, Kanagawa Children's Medical Center, 2-138-4,
terns, as excessive dosing and polypharmacy of antip-
Mutsukawa, Minami-ku, Yokohama, Kanagawa 232-8555, Japan.
sychotics are prevalent in East Asia.7,8
Within mental health care units, patients are
Received 10 September 2010; revised 4 August 2012; accepted 11September 2012.
often administered unscheduled medications. The
2013 The Authors
Psychiatry and Clinical Neurosciences 2013 Japanese Society of Psychiatry and Neurology
J. Fujita
et al.
Psychiatry and Clinical Neurosciences 2013;
67: 345–351
unscheduled medications fall into two categories: stat
prescribed and administered before regular antipsy-
medication and p.r.n. medication. Although these
chotic medications have had a chance to take effect.
categories are not clearly differentiated in previous
In the present multi-center study, we investigated
studies,9 stat medication usually refers to medication
whether the prescription and administration of p.r.n.
prescribed and administered on the basis of doctors'
antipsychotics to agitated patients with schizophre-
decisions in addition to regularly prescribed medica-
nia increased the risk of excessive dosing and polyp-
tions, whereas p.r.n. medication refers to medication
harmacy of antipsychotics in acute care settings.
prescribed by doctors in advance, and administrationon an as-needed basis according to nurses' clinicaljudgment under doctors' instructions. The use of
p.r.n. psychotropic medication is a widespread butnot fully proven interim method of treating acute
psychotic symptoms or behavioral disturbances
Twelve psychiatric hospitals were invited to an
thought to be secondary to psychotic illness.10 Antip-
explanatory meeting regarding this survey. These
sychotics are one class of drug used as a p.r.n. psy-
hospitals were recruited at the research request of
chotropic medication.11,12 A previous study showed
the Japanese Psychiatric Nurses Association (JPNA).
that most psychotic patients are administered at least
Of these recruited institutions, 17 acute psychiatric
one dose of p.r.n. antipsychotic during their hospital
wards in nine hospitals agreed to participate in this
stay.13 Furthermore, patients with schizophrenia in
survey. To relieve the burden on medical staff and to
acute mental health-care settings may be given p.r.n.
encourage participation in the study, the survey was
psychotropic medications frequently14 and at high
conducted using a single-day method. Participating
doses.9 The main disadvantage of this practice is the
wards were asked to submit data for all patients who
misuse of medication, that is, the administration of
occupied a bed in the ward for a 24-h period, includ-
too much medication or the administration of medi-
ing both day and night shifts. The survey day was
cation too quickly.15 This misuse may be caused by
selected by the chief nurse in each ward from among
variations in nurses' opinions regarding the need
5 weekdays in January 2008. The chief nurses in each
for p.r.n. psychotics, punitive indications, or over-
ward were asked to fill out the survey sheets and to
reliance on medication.16
provide details of the prescription and administra-
Recent studies revealed that cultural factors and the
tion of regular medication and p.r.n. psychotropic
practice of adding p.r.n. psychotropic medication to
medication. All 17 participating psychiatric wards
regular medicine might increase the risk for excessive
were considered acute psychiatric wards as defined by
dosing and polypharmacy of antipsychotics.17,18
the Ministry of Health, Labor and Welfare of Japan.
There are no published reports of prescription
Figure 1 shows a flow diagram of the recruitment of
surveys assessing the use of p.r.n. psychotropic medi-
participants. Patients with a diagnosis of schizophre-
cation, excessive dosing, or polypharmacy of antipsy-
nia or related disorders (ICD-10, F21-29) who were
chotics in East Asia. Previous studies have indicated
prescribed at least one antipsychotic agent as regular
that more Japanese patients with schizophrenia are
therapy were included in the study. The total number
prescribed antipsychotics at high doses than patientsin other East Asian countries.7,8 It is thus important toinvestigate the risk of excessive dosing and polyphar-macy of antipsychotics caused by p.r.n. psychotropic
Invited to participate (24 wards in 12 hospitals)
medication in Japan.
Declined (7 wards in 3 hospitals)
Agreed to participate (17 wards in 9 hospitals)
Aims of the study
All the inpatients in 17 wards at the survey day (
n = 789)
Agitation is commonly cited as the rationale for both
Inpatients who did not meet the
the prescription and administration of p.r.n. psycho-
inclusion criteria (
n = 376)
tropic medication.19 Patients with schizophrenia or
Inpatients who met the inclusion criteria (
n = 413)
related disorders who are admitted to acute psychiat-ric units may urgently require the reduction of agita-
Figure 1. Inclusion criteria: ICD-10-F2 and prescribed at least
tion, and thus p.r.n. psychotropic medication is often
one antipsychotic as regular medication.
2013 The AuthorsPsychiatry and Clinical Neurosciences 2013 Japanese Society of Psychiatry and Neurology
Psychiatry and Clinical Neurosciences 2013;
67: 345–351
Polypharmacy caused by p.r.n. medication
of inpatients in the 17 wards on the survey day was
dosing group,' regardless of whether the medication
789. Out of a total of 789 inpatients, 440 had schizo-
administered was regular medication only or regular
phrenia or related disorders. Of these, 10 patients were
medication plus p.r.n. medication. All dosages of
excluded from the analysis because of missing data,
antipsychotic drugs were converted into chlorprom-
and an additional 17 patients were excluded because
azine equivalents to facilitate comparisons.20
they had not been prescribed antipsychotics as a
We found that the maximum dose of p.r.n. psycho-
regular medication. Thus, we used data from 413
tropic medication varied by nurse and ward. Simi-
patients for our analysis. Of these 413 patients, the
larly, the reasons that doctors prescribed p.r.n.
number (%) of male patients was 245 (59.3%). The
psychotropic medication to patients also varied. To
mean age of the patients was 49.1 (SD 15.6, range
help control for these variations, our study group,
15–83). The number of patients who had undergone
including one expert psychiatric nurse, one expert
involuntary admission was 282 (68.3%). The median
psychiatric pharmacologist, and one psychiatrist with
length of stay in days of the 413 patients was 180.
sufficient clinical experience, first determined the keyreasons for the prescription and administration ofp.r.n. psychotropic medication; it was concluded that
all of these reasons related to the reduction of patient
In the present study, as part of a study carried out by
‘agitation.' Based on previous studies,16,17 the follow-
the National Program of Drug Optimization for Psy-
ing five terms were chosen to represent agitation:
chiatric Services (P-DOPS), a cross-sectional survey
‘unstable mental status,' ‘distress,' ‘restlessness,'
was conducted to clarify the current status of daily
‘physically or verbally threatening behavior,' and
psychiatric medication use. This study was approved
‘loud/disruptive behavior.' Second, we focused on
by the institutional review board of the National
two aspects of antipsychotic therapy for patients with
Centre of Neurology and Psychiatry.
schizophrenia: (i) initial prescription of p.r.n. antip-
The following data were collected for each patient:
sychotics; and (ii) administration of p.r.n. antipsy-
demographic variables, age, sex, mental health act
chotic therapy on the survey day. Although there were
status, length of stay in days, and ICD-10 diagnostic
126 patients whose p.r.n. prescription included
grouping. We collected the drug names and daily
several medications (i.e., risperidone tablet 1 mg at
dosage for each regular prescription, and the drug
first, haloperidol tablet 5 mg next, and finally halo-
name, route of administration, dose, indications for
peridol 5 mg i.m. injection), we used the first p.r.n.
use and prescription dosage for each p.r.n. prescrip-
prescription and administration in this study.
tion or administration. The data of patients with adiagnosis of schizophrenia or related disorders
whose regular medication contained one or more
In the present study, we used McNemar's test to
antipsychotics were used.
evaluate differences in the proportions of patients
In this survey, we operationally defined appropri-
whose antipsychotic prescriptions met the criteria for
ate prescribing patterns in two ways. First, a single
excessive dosing or polypharmacy before (i.e., regular
antipsychotic was recommended.5,6 We defined
medication only) and after prescribed p.r.n. antipsy-
patients who were prescribed a combination of two
chotics were added to their regular medication (i.e.,
or more kinds of antipsychotics as the ‘polypharmacy
regular medication plus p.r.n. antipsychotics). We
group.' The polypharmacy group was divided into
defined the level of significance at
P < 0.05.
three subgroups: polypharmacy with first-generation
Analyses were performed using SPSS 11.0 (SPSS,
antipsychotics (FGA), referred to as type 1 polyphar-
Chicago, IL, USA).21
macy; polypharmacy with second-generation antip-sychotics (SGA), referred to as type 2 polypharmacy;
and polypharmacy with both FGA and SGA antipsy-chotics, referred to as type 3 polypharmacy. Second,
Descriptive statistics regarding the use of
the standard daily dosage of an individual antipsy-
antipsychotics with excessive dosing and
chotic is recommended to be less than a 1000-mg
polypharmacy as regular medication
chlorpromazine-equivalent dose (mg CPZ eq.).3 Wedefined patients who were prescribed a 1000-mg CPZ
Among 413 patients, the mean antipsychotics dosage
eq. dose or more in a single day as the ‘excessive
was 942.1 mg CPZ eq. (SD 805.6), and the mean
2013 The Authors
Psychiatry and Clinical Neurosciences 2013 Japanese Society of Psychiatry and Neurology
J. Fujita
et al.
Psychiatry and Clinical Neurosciences 2013;
67: 345–351
number of antipsychotics was 2.2 (SD 1.2). With
respect to prescriptions outside of the recommended
prescription guidelines, the excessive dosing group
included 150 patients (36.4%), and the polyphar-
macy group included 276 patients (66.9%).
Patterns of prescribing p.r.n. for agitated
patients with schizophrenia
Out of the total of 413 patients, 312 (75.5%) wereprescribed at least one p.r.n. psychotropic medicationby doctors for agitation. Of these 312 patients, 281
Excessive dosing group*
Polypharmacy group
(90.1%) were prescribed antipsychotics, and 31(9.9%) were prescribed agents other than antipsy-
Figure 2. Total number of patients prescribed pro re nata
chotics. The remaining 101 patients (24.2%) were
(p.r.n.) antipsychotics was 281.*1000 mg chlorpromazine eq.
not prescribed p.r.n. medication for agitation.
Of the 281 agitated patients who were prescribed
**McNemar-test,
P < 0.001. , Regular only; , Regular + pre-
p.r.n. with antipsychotics, 109 (38.8%) received
scribed p.r.n. antipsychotics (not including benzodiazepinesand other psychotropics).
excessive dosing and 186 (66.2%) were administeredpolypharmacy due to the regular medications pre-scribed to them.
macy of antipsychotics increased to 257 (91.5%):
Of the 281 agitated patients who were prescribed
196 (69.8%) with type 3 polypharmacy, 19 (6.8%)
p.r.n. with antipsychotics, 171 (60.9%) were pre-
with type 1, and 42 (14.9%) with type 2.
scribed risperidone, and 23 (8.2%) were prescribed
When these 281 patients were administered only
another SGA. Meanwhile, 36 (12.8%) were pre-
their regular medication, the mean dosage of regular
scribed haloperidol, and 52 (18.5%) were prescribed
antipsychotics was 1016.7 mg CPZ eq. (SD 884.5),
another FGA.
and the mean number of antipsychotics was 2.3 (SD1.3). When these patients were administered regularmedication together with p.r.n. antipsychotics for
Risk of excessive dosing and polypharmacy
agitation, the mean dosage increased to 1220.0 mg
caused by p.r.n.
CPZ eq. (SD 920.9), and the mean number of antip-
sychotics increased to 2.8 (SD 1.2).
When p.r.n psychotropic medication for agitation is
Actual administration on the survey day
added to the patient's regular medication by a nurse,
Seventeen patients (4.1%) were actually adminis-
the total daily dose of antipsychotic medications may
tered p.r.n. psychotropic medication for agitation on
increase. Figure 2 shows the changes in the number
the day of the survey. After the administration of
of patients in the excessive dosing group and the
p.r.n. antipsychotics, the number of patients in the
polypharmacy groups among the 281 patients who
excessive dosing group increased from 10 (58.8%) to
were prescribed p.r.n. antipsychotics. McNemar's test
13 (76.5%) patients, while that in the polypharmacy
revealed a significant increase in the proportion of
group increased from 14 (82.4%) to 17 (100.0%).
patients with excessive dosing (
P < 0.001) and polyp-
McNemar's test revealed no significant differences
harmacy (
P < 0.001) after p.r.n. psychotropic medi-
between these groups. Of the 281 patients with an
cation was added to regular medication.
antipsychotic p.r.n. prescription, the 17 patients actu-
When these 281 patients were administered only
ally administered p.r.n. had a median length of stay
their regular medication, the total number of patients
of 1622 days, while that for the 264 patients who
with polypharmacy of antipsychotics was 186
were not administered any p.r.n. was 172 days.
(66.2%): 128 (45.6%) with type 3 polypharmacy, 31(11.0%) with type 1, and 27 (9.6%) with type 2.
When these patients were administered regularmedication together with p.r.n. antipsychotics for
In the present study, at least one p.r.n. psychotropic
agitation, the total number of patients with polyphar-
medication for agitation was prescribed to three-
2013 The AuthorsPsychiatry and Clinical Neurosciences 2013 Japanese Society of Psychiatry and Neurology
Psychiatry and Clinical Neurosciences 2013;
67: 345–351
Polypharmacy caused by p.r.n. medication
quarters of patients with schizophrenia. Of those
without optimization of the practice of prescribing
p.r.n. medications, nine-tenths were antipsychotics.
and administering p.r.n. psychotropic medication.
Of these antipsychotics, 70% were SGA. Among the
Currently, regarding stat psychotropic medication
281 patients who were prescribed p.r.n. antipsychot-
that is mainly the responsibility of doctors, we can
ics for ‘agitation,' the numbers of patients with exces-
refer to the guidelines for standard pharmacotherapy
sive dosing and polypharmacy increased significantly
for patients with schizophrenia5,6 and to the guide-
after p.r.n. antipsychotics were added to the patients'
lines for standard management of violence or
regular medications, and the mean dosage and total
agitation.26 These guidelines suggest that rapid tran-
daily doses of antipsychotics increased by 20%.
quillization as an intervention for the short-term
Actually, 4% of patients who were prescribed p.r.n.
management of agitation with benzodiazepines or
antipsychotics for ‘agitation,' were administered at
antipsychotics is both reasonably effective and safe.
least one p.r.n. psychotropic medication on only one
However, regarding p.r.n. psychotropic medication
survey day, and all the patients received excessive
with which nurses' clinical decisions are closely
dosing or polypharmacy of antipsychotics as a result.
involved, the guidelines suggest that the use of p.r.n.
These patients stayed longer than patients who were
medication for the short-term management of agita-
not actually administered p.r.n. antipsychotics on the
tion in psychiatric in-patient settings is inconsistent
and the medication may not be appropriately admin-
The present study suggests that the prescription of
istered or monitored.26 There is no high-quality evi-
p.r.n. psychotropic medication may lead to the
dence regarding the risks and benefits of p.r.n.
administration of antipsychotics outside of recom-
mended prescription guidelines. In particular, there
In many circumstances, there are no clear-cut clini-
are serious problems related to the prescription of
cal guidelines regarding p.r.n. psychotropic medica-
p.r.n. psychotropic medications for agitated patients
tion. It is possible that a non-pharmacological
with schizophrenia who are vulnerable to repeated
approach27 or a benzodiazepine28 may be a better
dosing.9,14,22 In the present study, patients who were
initial approach than p.r.n. antipsychotics in agitated
administered p.r.n. antipsychotics on the survey day
patients with schizophrenia who do not require rapid
stayed longer in acute psychiatric wards and received
tranquilization. However, a previous study14 found
more excessive dosing and polypharmacy of antipsy-
that barriers to the acute use of benzodiazepines
chotic medication than other patients. The previous
include doubts about their efficacy and concerns
study showed that p.r.n. psychotropic medications
about drug dependence, despite evidence showing
are likely to be administered to patients in the first 4
the safety and effectiveness of these drugs.28 It is pos-
days of admission, or to those who remain in hospi-
sible that the present findings reflect the belief among
tal for longer periods of time.19 The patients who
Japanese psychiatrists and nurses that antipsychotics
remain in hospital for longer periods may be refrac-
are more effective than benzodiazepines for agitated
tory cases, and may be more vulnerable to repeated
patients with schizophrenia.
doses of p.r.n. psychotropic medication. In those
In general, although SGA have fewer side-effects
cases in which p.r.n. antipsychotics were prescribed
than FGA,29,30 SGA should be prescribed carefully in
and administered repeatedly and over a long term,
terms of their additional use as p.r.n. psychotropic
p.r.n. antipsychotics were shown to cause hidden
medications. Evidence suggests that these drugs can
excessive dosing and polypharmacy of antipsychotic
cause adverse effects, such as Parkinson's-like syn-
medication.17,18 The p.r.n. process in psychiatric
drome, sexual dysfunction, and metabolic syndrome,
wards is complicated and potentially allows nurses to
which may affect treatment adherence.31,32 All three
use their clinical judgment regarding the administra-
types of polypharmacy of antipsychotics as described
tion of p.r.n. medications prescribed by doctors.23
in the present study can alter the predicted efficacy
The proper use of p.r.n. antipsychotics by nurses
and adverse effects of medications through complex
depends on several factors, including clinical set-
pharmacokinetics.33–35 The risk-to-benefit ratio for
tings,22 preference for medication,24 relationship with
the use of SGA on a p.r.n. basis may not be accept-
doctors,17,25 nursing experience, nursing technique,
able.36 It is recommended that one antipsychotic
and working environment.15
should be added to another antipsychotic only with
The problems of hidden excessive dosing and
careful consideration.34 However, the present study
polypharmacy of antipsychotics cannot be solved
suggests that the use of SGA as p.r.n. psychotropic
2013 The Authors
Psychiatry and Clinical Neurosciences 2013 Japanese Society of Psychiatry and Neurology
J. Fujita
et al.
Psychiatry and Clinical Neurosciences 2013;
67: 345–351
medications is common, and this practice may
researchers would also like to thank the hospital staff
induce a high percentage of combination therapies,
who assisted with the survey.
such as type 2 polypharmacy or type 3 polypharmacy.
No author reports that there is any conflict of inter-
Some studies and expert-consensus statements rec-
ests to declare.
ommend that both doctors and nurses should care-fully examine the necessity for the prescription andadministration of p.r.n. antipsychotics, and that
psychiatric services should provide educationalprograms for mental health professionals and
1. Centorrino F, Goren JL, Hennen J, Salvatore P, Kelleher JP,
reach consensus about the proper way to use p.r.n.
Baldessarini RJ. Multiple versus single antipsychotic agents
medications.25,37 Doctors and nurses should attempt
for hospitalized psychiatric patients: Case control study of
various approaches to minimize the unnecessary use
risks versus benefits.
Am. J. Psychiatry 2004;
161: 700–706.
2. Harrington M, Lelliott C, Paton C, Okocha C, Duffett R,
of unscheduled psychotropic medication.38 These
Sensky T. The results of a multi center audit of the pre-
approaches might be reviewing clinical indications,
scribing of antipsychotic drugs for inpatients in UK.
frequency of administration, therapeutic benefits and
Psychiatr. Bull. 2002;
26: 414–418.
side-effects each week, for instance.5 Results in this
3. Baldessarini RJ, Cohen BM, Teicher MH. Significance of
study suggest that p.r.n. medication practice be listed
neuroleptic dose and plasma level in the pharmacological
as a quality indicator in psychiatric inpatient care.
treatment of psychoses.
Arch. Gen. Psychiatry 1988;
45:
The careful monitoring of p.r.n. medication practice
could improve the quality and safety of psychiatric
4. Joukamaa M, Heliovaara M, Knekt P, Aromaa A, Raitasalo
R, Lehtinen V. Schizophrenia, neuroleptic medication and
This study contains the limitation that few patients
mortality.
Br. J. Psychiatry 2006;
188: 122–127.
were administered p.r.n. due to the short-term study
5. National Institute for Health and Clinical Excellence
(NICE). Schizophrenia: core interventions in the treat-
period. We could not identify the potential for the
ment and management of schizophrenia in adults in
risk of excessive dosing and polypharmacy in patients
primary and secondary care 2009, [Cited March 2009.]
who were actually administered p.r.n. antipsychotics.
As this study was intended as a prescription survey,
not as a survey of patients in an interventional
6. Lehman AF, Lieberman JA.
Practice Guideline for the Treat-
manner, we could not gather complete profiles of
ment of Patients with Schizophrenia, 2nd edn. Arlington,
patients, including the clinical characteristics of
APA Practice Guidelines, 2004.
symptoms and co-morbidities.
7. Chong MY, Tan HC, Fujii S
et al. Antipsychotic drug pre-
In conclusion, p.r.n. antipsychotics may cause
scription for schizophrenia in East Asia: Rationale for
hidden excessive dosing and polypharmacy of antip-
change.
Psychiatry Clin. Neurosci. 2004;
58: 61–67.
sychotics. Our results indicate the importance of
8. Shinfuku N, Tan C. Pharmacotherapy for schizophrenic
inpatients in East Asia – Changes and challenges.
Int. Rev.
monitoring the prescription and administration of
Psychiatry 2008;
20: 460–468.
p.r.n. antipsychotic medication to patients with
9. Craig TJ, Bracken J. An epidemiologic study of prn/stat
medication use in a state psychiatric hospital.
Ann. Clin.
Psychiatry 1995;
7: 57–64.
10. Chakrabarti A, Whicher E, Morrison M, Douglas-Hall P.
‘As required' medication regimens for seriously mentally
ill people in hospital.
Cochrane Database Syst. Rev. 2007;
3:
This study was conducted with the aid of Sponsored
CD003441. (Cited March 2007). Available from URL:
Research on Psychiatric and Neurological Diseases
and Mental Health Research 2008, supported by the
Ministry of Health, Labor and Welfare, Japan (Grant
11. Curtis J, Capp K. Administration of ‘as needed' psychotro-
pic medication: A retrospective study.
Int. J. Ment. Health
No; 20-8). The opinions expressed in this article are
Nurs. 2003;
12: 229–234.
those of the authors and do not represent the official
12. Craven JL, Voore PM, Voineskos G. PRN medication for
views of the Ministry. We are especially grateful to the
psychiatric inpatients.
Can. J. Psychiatry 1987;
32: 199–
members of the Japan Psychiatric Nurses Association,
Keiko Matsumoto PhD, Mr Tamio Sueyasu MNSc,
13. Geffen J, Sorensen L, Stokes J, Cameron A, Roberts MS,
and Ms Sakae Nakano for data collection. The
Geffen L. Pro re nata medication for psychoses: An audit of
2013 The AuthorsPsychiatry and Clinical Neurosciences 2013 Japanese Society of Psychiatry and Neurology
Psychiatry and Clinical Neurosciences 2013;
67: 345–351
Polypharmacy caused by p.r.n. medication
practice in two metropolitan hospitals.
Aust. N. Z. J.
settings and emergency departments [Cited March 2006.]
Psychiatry 2002;
36: 649–656.
Available from URL: http://www.nice.org.uk/CG25.
14. Stein-Parbury J, Reid K, Smith N, Mouhanna D, Lamout F.
27. Campbell R, Simpson G. Alternative approaches in the
Use of pro re nata medications in acute inpatient care.
treatment of psychotic agitation.
Psychosomatics 1986;
27
Aust. N. Z. J. Psychiatry 2008;
42: 283–292.
(Suppl. 1): 23–26.
15. Baker JA, Lovell K, Harris N. Mental health professionals'
28. Wolkowitz O, Pickar D. Benzodiazepines in the treatment
psychotropic pro re nata (p.r.n.) medication practices in
of schizophrenia: a review and reappraisal.
Am. J. Psychia-
acute mental health care: A qualitative study.
Gen. Hosp.
try 1991;
148: 714–726.
Psychiatry 2007;
29: 163–168.
29. Currier GW, Simpson GM. Risperidone liquid concentrate
16. Bowden MF. Audit: Prescription of ‘as required' (p.r.n.)
and oral lorazepam versus intramuscular haloperidol and
medication in an in-patient setting.
Psychiatr. Bull. 1999;
intramuscular lorazepam for treatment of psychotic agita-
tion.
J. Clin. Psychiatry 2001;
62: 153–157.
17. Milton J, Lawton J, Smith M, Buckley A. Hidden high dose
30. Canas F. Management of agitation in the acute psychotic
antipsychotic prescribing: effects of prn doses.
Psychiatr.
patient – efficacy without excessive sedation.
Eur. Neurop-
Bull. 1998;
22: 675–677.
sychopharmacol. 2007;
17: s108–s114.
18. Paton C, Barnes TRE, Cavanagh M, Taylor D, Lelloit
31. Moncrieff J, Cohen D, Mason JP. The subjective experience
P. High-dose and combination antipsychotic prescribing
of taking antipsychotic medication: A content analysis of
in acute adult wards in the UK: the challenges posed
internet data.
Acta Psychiatr. Scand. 2009;
120: 102–111.
by p.r.n. prescribing.
Br. J. Psychiatry 2008;
192: 435–
32. Carnahan RM, Lund BC, Perry PJ, Chrischilles EA.
Increased risk of extrapyramidal side effect treatment asso-
19. Baker JA, Lovell K, Harris N. A best-evidence synthesis
ciated with atypical antipsychotic polytherapy.
Acta Psychi-
review of the administration of psychotropic pro re nata
atr. Scand. 2006;
113: 135–141.
(PRN) medication in inpatient mental health settings.
J.
33. Freudenreich O, Goff DC. Antipsychotic combination
Clin. Nurs. 2008;
17: 1122–1131.
therapy in schizophrenia. A review of efficacy and risk of
20. Inagaki A, Inada S. Dose equivalence of psychotropic
current combinations.
Acta Psychiatr. Scand. 2002;
106:
drugs, 2006 version.
Rinsho Seishin Yakuri 2006;
9: 1443–
1447 (in Japanese).
34. Weiden PJ, Preskorn SH, Fahnestock PA
et al. Translating
21. Norusis MJ, SPSS inc.
SPSS 11.0 Guide to Data Analysis.
the psychopharmacology of antipsychotics to individual-
Prentice Hall, Upper Saddle River, NJ, 2002.
ized treatment for severe mental illness: a road map.
J.
22. McLearen S, Browne FWA, Taylor PL. A study of psycho-
Clin. Psychiatry 2007;
68 (Suppl. 7): 1–48.
tropic medication given ‘as required' in a regional secure
35. Conley RR, Kelly DL. Drug-drug interactions associated
unit.
Br. J. Psychiatry 1990;
156: 732–735.
with second generation antipsychotics: considerations for
23. Usher K, Holmes C, Lindsay D, Luck L. PRN psychotropic
clinicians and patients.
Psychopharmacol. Bull. 2007;
40:
medications: the need for nursing research.
Contemp. Nurs.
2003;
14: 248–257.
36. Demczar D, Levin G. Use of atypical antipsychotics on an
24. Geffen J, Cameron A, Sorensen L, Stokes J, Roberts MS,
as needed basis.
J. Pharm. Tech. 1996;
12: 145–148.
Geffen L. Pro re nata medication for psychoses: the knowl-
37. Baker JA, Lovell K, Harris N, Campbell M. Multidisci-
edge and beliefs of doctors and nurses.
Aust. N. Z. J.
plinary consensus of best practice for pro re nata (PRN)
Psychiatry 2002;
36: 642–648.
psychotropic medications within acute mental health set-
25. Ito H, Koyama A, Higuchi T. Polypharmacy and excessive
tings: A Delphi study.
J. Psychiatr. Ment. Health Nurs. 2007;
dosing: psychiatrists' perceptions of antipsychotic drug
prescription.
Br. J. Psychiatry 2005;
187: 243–247.
38. Thapa PB, Palmer SL, Owen RR, Huntley AL, Clardy JA,
26. National Institute for Health and Clinical Excellence
Miller LH. PRN (as needed) orders and exposure of psy-
chiatric inpatients to unnecessary psychotropic medica-
disturbed/violent behaviour in in-patient psychiatric
tions.
Psychiatr. Serv. 2003;
54: 1282–1286.
2013 The Authors
Psychiatry and Clinical Neurosciences 2013 Japanese Society of Psychiatry and Neurology
Source: http://researchmap.jp/?action=cv_download_main&upload_id=92540
Comprehensive Capacity Assessment of Health Laboratory Services in Nepal National Public Health laboratory and WHO-Nepal Page 1 of 62 Comprehensive Capacity Assessment of Health Laboratory Services in Nepal Dr. Palpasa Kansakar, Ph.D. (Microbiology) Mr. Binod Kumar Yadav, M.Sc (Biochemistry) Mr Krishna Rijal, CMLT Page 2 of 62
KEPPRA® (levetiracetam) Rx 250 mg, 500 mg, 750 mg, and 1000 mg tablets 100 mg/mL oral solution DESCRIPTION KEPPRA is an antiepileptic drug available as 250 mg (blue), 500 mg (yellow), 750 mg (orange), and 1000 mg (white) tablets and as a clear, colorless, grape-flavored liquid (100 mg/mL) for oral administration. The chemical name of levetiracetam, a single enantiomer, is (-)-(S)-α-ethyl-2-oxo-1-pyrrolidine acetamide, its molecular formula is C8H14N2O2 and its molecular weight is 170.21.